July 23, 2025 marks a turning point in global clinical research: the official entry into force of the updated ICH Good Clinical Practice E6(R3) guidelines. More than a regulatory revision, this update—led by the International Council for Harmonisation (ICH)—initiates a new era of quality, transparency, digitization, and patient-centricity.
The changes affect the entire clinical research ecosystem, including sponsors, CROs, clinical sites, service providers, and digital platforms. Among the key players adapting to this evolution is AICRO, the Italian association of CROs, which is redefining its structure to meet the future of compliant research.
What Is GCP E6(R3) and What Changes?
Good Clinical Practice (GCP) defines the global ethical and scientific quality standard for clinical trials. The E6(R3) revision introduces major upgrades:
- Adoption of quality-by-design principles
- Greater emphasis on patient centricity
- Focus on risk-based monitoring
- Recognition of digital technologies and decentralized processes
- Clearer roles and responsibilities for all stakeholders, not just sponsors and CROs
The goal is to embed quality from the earliest stages of trial planning—making compliant tools and collaborative processes essential.
AICRO’s Role in the New Landscape
In response to E6(R3), AICRO has launched an important organizational update: the formal inclusion of Service Providers in its membership base. This aligns with the new GCP vision, where technology providers and domain specialists are acknowledged as integral players in the research chain.
The initiative promotes a collaborative ecosystem—where sponsors, CROs, providers, and clinical sites work transparently and efficiently to deliver patient-centered trials.
Service Providers in Clinical Research: A Concrete Opportunity
E6(R3) recognizes Service Providers as essential to trial quality and success. These include:
- Providers of EDC, RTSM, eTMF, ePRO platforms
- Specialists in data management, biostatistics, pharmacovigilance
- Companies offering AI tools and audit-ready software
By formally acknowledging their contribution, the new GCPs ensure:
- Higher trial efficiency
- Better data traceability
- Shared accountability for data quality and compliance
However, these responsibilities also require compliance-ready tools and processes.
Technology’s Role in the Future of Clinical Trials
In this new scenario, digital platforms like ACTide are essential. Designed to comply with updated GCP requirements, ACTide provides:
- Configurable eCRFs aligned with GCP and CDISC standards
- Real-time quality control and full audit trail
- Automated document workflows and eTMF
- Collaborative access for sponsors, CROs, and service providers
- Full traceability and interoperability
ACTide supports research teams with a unified and compliant platform that simplifies trial operations and risk management.
Want to see how ACTide can simplify your clinical trial management under the new GCP E6(R3) guidelines?
GCP E6(R3): a turning point for clinical research
The ICH E6(R3) guidelines reshape the clinical research ecosystem. AICRO is embracing this shift, opening to Service Providers and promoting a more integrated, transparent, and patient-focused approach.
Now is the time for professionals to upskill, prepare, and adopt digital solutions that align with these new principles.
Learn how ACTide can help you navigate the GCP E6(R3) transition